Previous close | 18.65 |
Open | N/A |
Bid | 19.00 |
Ask | 21.30 |
Strike | 35.00 |
Expiry date | 2024-07-19 |
Day's range | 18.65 - 18.65 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Ohtuvayre is indicated for the maintenance treatment of COPD allowing for broad use in COPD patients First inhaled COPD treatment providing bronchodilation and non-steroidal anti-inflammatory effects Conference call tomorrow at 8:30 a.m. EDT / 1:30 p.m. BST LONDON and RALEIGH, N.C., June 26, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces the US Food and Drug Administration (“FDA”) approved Ohtuvayre (ensifentrine) for the maintenance treat
There hasn't been a new COPD treatment in years. But Regeneron stock analysts are closely watching a pair of key FDA decisions.
Insights into Verona Pharma's First Quarter Performance and Future Prospects